Blood tests measure the level of PSA protein, produced by the prostate gland, and may help detect early signs of prostate ...

In an effort to find new treatments for castrate-resistant prostate cancer, a TTUHSC research team led by Srinivas Nandana, ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...